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Purpose. Up to 30% of international travelers are affected by travelers’ diarrhea (TD). Reliable data on the etiology of TD is lacking.
Sufficient laboratory capacity at travel destinations is often unavailable and transporting conventional stool samples to the home
country is inconvenient. We evaluated the use of Hemoccult cards for stool sampling combined with a multiplex PCR for the
detection of model viral, bacterial, and protozoal TD pathogens.Methods. Following the creation of serial dilutions for each model
pathogen, last positive dilution steps (LPDs) and thereof calculated last positive sample concentrations (LPCs) were compared
between conventional stool samples and card samples. Furthermore, card samples were tested after a prolonged time interval
simulating storage during a travel duration of up to 6 weeks. Results. The LPDs/LPCs were comparable to testing of conventional
stool samples. After storage onHemoccult cards, the recovery rate was 97.6% forC. jejuni, 100% forE. histolytica, 97.6% for norovirus
GI, and 100% for GII. Detection of expected pathogens was possible at weekly intervals up to 42 days. Conclusion. Stool samples on
Hemoccult cards stored at room temperature can be used in combination with a multiplex PCR as a reliable tool for testing of TD
pathogens.
1. Introduction
Thenumber of international travelers is continuously increas-
ing and has passed the mark of one billion in 2013 for the
first time. Travel destinations also include countries with low
economic and hygienic standards; many of them are located
in the tropical and subtropical regions. Therefore, travelers
are often exposed to higher health risks, especially from
infectious diseases. The GeoSentinel-Network, consisting of
worldwide distributed travel clinics, identified important
illnesses associated with international travels. Besides sys-
temic febrile illnesses and dermatologic disorders, diarrheal
illnesses are a main risk for international travelers [1]. This
disease entity is described as travelers diarrhea (TD) with
classic TD defined as the occurrence of three or more
unformed stools in 24 hours in combination with at least one
additional symptom like urgency, abdominal cramps, fever,
or bloody diarrhea [2]. Although TD rates have declined as
a result of improved hygienic conditions in the destination
countries, TD still affects up to 30% of all travelers [3, 4].
The risk for TD depends on the type and destination of the
travel. TD usually starts in the first week of the travel and
is commonly a self-limiting disease lasting usually up to 5
days [5]. In about 75% of cases in which detection of the
responsible pathogen was possible bacterial pathogens were
the cause of TD, especially intestinal pathogenic Escherichia
coli, Salmonella spp., Shigella spp., and Campylobacter jejuni
[6, 7]. Other important pathogens are viruses including
norovirus and rotavirus affecting up to 15% of travelers with
TD [6–8]. In the case of persistent diarrhea lasting more
than 14 days protozoa like Giardia lamblia or Entamoeba
histolytica have to be considered [7]. As most of the cases
of TD are resolved before the end of the travel and suffi-
cient laboratory diagnostic capacities are seldom available
at the travel destinations, data on the etiologic spectrum
of TD occurring during the periods of travel is scarce. As
conventional stool samples are inconvenient to handle for the
traveler and an adequate cooling chain is difficult to maintain
inmost travel destinations, the conduct of studies concerning
the etiology of TD is hampered. Conventional Hemoccult
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stool cards (Beckman Coulter Inc., Brea, CA, US) are an
accepted tool for the collection of stool samples in order to
test for the existence of occult blood. They are easy to handle
and can be hygienically stored during travel. Grimes et al.
have shown that the detection of enteropathogens, especially
enterotoxigenic E. coli and enteroaggregative E. coli from
Hemoccult cards by polymerase chain reaction (PCR), can be
successfully achieved for up to 14 months of storage at room
temperature [9]. Commercially available multiplex PCR test-
kits like the Gastrointestinal Pathogen Panel (GPP, Luminex,
Austin, TX, USA) allow the simultaneous detection of up
to 15 enteropathogens causing TD. Therefore, sampling on
stool cards in combination with a multiplex PCR may be a
convenient tool for testing stool samples for the etiology of
TD.
To evaluate the performance of Hemoccult cards for stool
sampling in combination with the GPP for the detection
of model bacterial, viral, and protozoal TD pathogens, this
study determined the LPDs and, if available, the LPCs were
thereof calculated. LPDs and LPCs were then compared
between conventional stool samples and Hemoccult cards.
Subsequently, samples on stool cards were tested after a
prolonged time interval simulating a travel duration of up to
6 weeks.
2. Material and Methods
2.1. Preparation of the Spiked Stools Samples and Norovirus
GI/II Samples for Determining the LPDs/LPCs and for Storage
on Hemoccult Cards. Six different formed human stool sam-
ples were obtained fromour outpatient laboratory asmatrices
for spiking with C. jejuni or E. histolytica. These samples had
been tested negative for enteropathogenic bacteria (C. jejuni,
Shigella spp., and Salmonella spp.) by routine culture and for
intestinal parasites by microscopic stool examination in the
laboratories of the Department for Infectious Diseases and
Tropical Medicine (DITM, accredited according to DIN EN
ISO 15189). Samples were additionally tested negative for E.
histolytica by PCR with the GPP. After routine testing, the
samples were stored at −20∘C until further processing in this
study.
C. jejuni subsp. jejuni cultures (DSM Nr. 4688 Mar 09)
were inoculated on blood agar from cryobeads and were
cultivated at 42∘C for 1-2 days. One loop-full (Hard Loop
10 𝜇L, VWR, Brescia, Italy) bacterial colonies were harvested
and dissolved in 1mL PBS.
E. histolytica samples (HK9 strain) stored in liquid nitro-
gen were thawed and grown in axenic culture in culture flasks
using TYI-S33 culture medium at 37∘C for 3-4 days, yielding
only trophozoites [10]. Viable amoeba were mobilized from
the inside wall by placing the culture flask into an ice water
bath and were harvested according to standardized proce-
dures as established in the accredited diagnostic laboratory
of the DITM. Viable amoeba were dissolved in 1mL PBS.
For determination of the concentration of Campylobacter
jejuni and E. histolytica, 10 𝜇L of the pathogen solution
was placed onto a Neubauer “improved” disposable count-
ing chamber (C-Chip, Biochrom, Berlin, Germany) and
counted according to the manufacturers recommendations.
For counting C. jejuni, a cold Ziehl-Neelsen stain was done
[11]. For E. histolytica, every visible trophozoite was counted
without staining.
For C. jejuni 100.000 organisms/mL and for E. histolytica
5500 organisms/mL were defined as the intended concen-
tration in the spiked stock stool sample to achieve a value
well above the limits of detection (LoDs) of the GPP (C.
jejuni: 60000CFU/mL, E. histolytica: 2150 cells/mL) for these
organisms as indicated by the manufacturer [12]. Usual
pathogen loads for C. jejuni are 106 to 109 colony forming
units (CFUs) per g stool [13]. Correct data on the pathogen
load of E. histolytica in stool samples of patients are not
readily available, as the evaluation by microscopy in stool
is unreliable and cannot discern between pathogenic and
apathogenic Entamoeba spp. [14]. Older literature data sug-
gest that Entamoeba infection will be detected by microscopy
in two stool examinations at a cyst excretion rate of 100.000 to
1.000.000 cysts per day [15].Three grams of the negative stool
matrices was diluted with PBS to a final volume of 30mL,
respectively, to achieve a diarrhea stool-like consistency and
to ensure an adequate amount of material for testing of native
samples and loading of the stool cards.
A part of each of the fluid stool matrices was then
combined with the calculated amount of culture fluid to
achieve the desired concentration of pathogens and a total
volume of 5mL of spiked stock stool sample for further
testing.
Additionally, six frozen norovirus GI and six frozen noro-
virus GII stool samples of patients were obtained from a
reference laboratory where they had been tested positive
by a quantitative in-house PCR (the corresponding cross-
threshold (Ct) values were provided by the reference lab-
oratory; Tables 1 and 2). Pathogen load for the norovirus
samples was unfortunately not available. The Ct values of
the samples were well in the range of detection of the
GPP. The corresponding LoDs of the GPP for norovirus
GI and GII are Ct 40.85 and Ct 37.16, respectively [12].
After thawing, three grams of each norovirus-stool sample
was diluted in phosphate buffered saline (PBS) to create a
final sample volume of 5mL with diarrhea-like consistency.
For the storage trial a set of three norovirus GI and three
norovirus GII stool samples and for the serial dilutions a
different set of three norovirus GI and three norovirus GII
stool samples were used.
2.2. Preparation of Serial Dilutions for C. jejuni, E. histolytica,
and Norovirus GI/GII. For the serial dilutions, fluid stool
matrices, pathogen culture fluids, and spiked stock stool sam-
ples forC. jejuni and E. histolyticawere prepared as described
above. For C. jejuni and E. histolytica the dilution steps 1 : 1
(pathogen content: C. jejuni: 100.000 organisms/mL, E. his-
tolytica: 5500 organisms/mL), 1 : 2, 1 : 4, 1 : 8, and 1 : 16 were
prepared. For creating each dilution step a decreasing amount
of pathogen culture fluid was filled up with fluid stool
matrices to achieve a final volume of 2mL.
For three norovirus GI and GII samples, respectively,
dilution series consisting of the original pathogen stool
sample and the dilution steps 10−2, 10−4, 10−6, and 10−8 were
prepared. To generate the dilutions 1mL of the original
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Table 1: LPDs and LPCs of the serial dilutions for norovirus GI/GII, C. jejuni, and E. histolytica native and card samples.
Pathogen Conventional sample Stool card sample
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3
Norovirus GI 10−2a 10−2a 10−6a 10−2a 10−2a 10−8a
Norovirus GII 10−6a 10−4a 10−2a 10−8a 10−2a 10−4a
C. jejuni 1 : 8 1 : 4 1 : 8 1 : 8 1 : 8 1 : 8
12.500/mL 25.000/mL 12.500/mL 12.500/mL 12.500/mL 12.500/mL
E. histolytica 1 : 16 1 : 8 1 : 16 1 : 16 1 : 16 1 : 16
344/mL 688/mL 344/mL 344/mL 344/mL 344/mL
LPCs are stated as calculated pathogen concentration (organisms/mL). aDilution steps retested by Microgen real-time PCR. Ct of norovirus (provided by
reference laboratory): GI sample 1, Ct 20; GI sample 2, Ct 20; GI sample 3, Ct 18; GII sample 1, Ct 17; GII sample 2, Ct 18; GII sample 3, Ct 18.
Table 2: Results of the storage trial for C. jejuni, E. histolytica, and norovirus GI/II.
Samplea Duplicate Day 0 Day 7/14/21 Day 28 Day 35/42 Detection rates
C. jejuni Samples 1, 2 1 pos pos pos pos
97.6%2 pos pos pos pos
C. jejuni Sample 3 1 pos pos neg pos
2 pos pos pos pos
E. histolytica Samples 1, 2, 3 1 pos pos pos pos 100%
2 pos pos pos pos
Norovirus GI Sample 1
1 pos pos pos pos
97.6%
Crypto. Crypto. Crypto. Crypto.
2 neg pos pos pos
Crypto. Crypto. Crypto.
Norovirus GI Samples 2, 3 1 pos pos pos pos
2 pos pos pos pos
Norovirus GII Samples 1, 2, 3 1 pos pos pos pos 100%
2 pos pos pos pos
pos, positive; neg, negative; Crypto, Cryptosporidium spp.
aPathogen content of samples: C. jejuni: 100.000 organisms/mL and E. histolytica: 5500 organisms/mL; Ct of norovirus (provided by reference laboratory): GI
sample 1, Ct 20; GI sample 2, Ct 22; GI sample 3, Ct 23; GII sample 1, Ct 11; GII sample 2, Ct 16; GII sample 3, Ct 19.
pathogen stool sample dilution was added to 9mL of PBS.
To achieve the desired concentrations this procedure was
repeated using 1mL of the last dilution step after vigorous
vortexing.
Besides the conventional samples of the dilution series,
for each sample and each step of the dilution series one
Hemoccult card was prepared. The two detection fields were
loaded with 200𝜇L of norovirus suspension or spiked stool
suspension.
2.3. Stability during Storage: Loading of Hemoccult Cards.
For the storage trial, three samples of norovirus GI and
norovirus GII, three Campylobacter-spiked stool matrices
(pathogen content: 100.000 organisms/mL), and three Enta-
moeba-spiked stool matrices (pathogen content: 5500 organ-
isms/mL)were used. For each of these samples sevenHemoc-
cult cards were prepared for duplicate testing at time points
0, 7, 14, 21, 28, 35, and 42 days as described above (Figure 1).
Furthermore, on day 0 for C. jejuni and E. histolytica samples
of the unspiked stool solution, spiked stock stool sample, and
the pathogen solution were prepared for testing. Concerning
the norovirus samples only the diluted stool samples were
additionally tested on day 0. The loaded Hemoccult cards
were stored in sealed zipper bags (without desiccants or oxy-
gen absorbers) at room temperature for the whole duration
of the storage trial.
2.4. Extraction of Samples on Cards and Conventional Stool
Samples by NucliSENS MiniMag. For the extraction of the
card samples, the two detection fields of the Hemoccult
cards were cut out using sterile single-use surgical blades
and forceps and transferred into vials containing 2mL
NucliSENS lysis buffer (bioMe´rieux SA, Marcy l’Etoile,
France). For extraction of the conventional stool samples,
a sample volume of 200 𝜇l of the unspiked stool solutions,
spiked stock stool samples, and the pathogen solutions
was added to 2mL lysis buffer. Samples were incubated
for 40 minutes (200 rpm, room temperature) in a ther-
moshaker (Ditabis, Pforzheim, Germany) before centrifu-
gation at 4000 rpm for five minutes. The supernatant was
then used for further processing. The extraction procedure
was done according to the manufacturers recommendation
and the RNA/DNA extracts were resuspended in 50 𝜇L of
elution buffer. DNA samples were immediately stored at





Day 42Day 35Day 28Day 21Day 14Day 7
Negative
stool matrix number 3
Negative
stool matrix number 2
Negative
stool matrix number 1
Noro G2 positive sample number 3
Noro G2 positive sample number 2
Noro G2 positive sample number 1
Noro G1 positive sample number 3
Noro G1 positive sample number 2
Noro G1 positive sample number 1
Applying samples on cardsSpiking Day 0
Figure 1: Schematic description of the preparation of the native and stool card samples for the storage trial.
−20∘C and RNA samples at −80∘C until further process-
ing.
2.5. Detection of Gastrointestinal Pathogens with the GPP.
10 𝜇L of extracted DNA/RNA samples was used for detection
with the GPP according to the manufacturer’s recommen-
dation. In brief, a (reverse transcription) PCR was done.
The PCR product was then combined with the detection
beads included in the GPP and amplicons were detected by
a MagPIX (Luminex, Austin, Texas, USA).
The LPDs were determined as the dilution step at which
both duplicates of the respective stool card or native sample
tested positive. The LPCs were, if available, then calculated
from the LPDs.
2.6. Retesting of Samples with Discordant Results. Discordant
PCR results between the tests of conventional and stool
card samples were retested with the GPP. If discrepancies
persisted, the samples were furthermore subjected to a com-
mercial real-time PCR for detection of the relevant pathogen
(Microgen, London, UK) according to the manufacturer’s
recommendation on a CFX96 real-time detection system
(BioRad, Munich, Germany).
3. Results
3.1. Serial Dilutions of C. jejuni and E. histolytica Samples.
The detection on stool cards was possible up to the dilution
step of 1 : 8mostlymatching the detection in the conventional
samples. In one C. jejuni containing sample the LPD of the
conventional sample was one step lower (1 : 4) than the card
sample (Table 1).
The E. histolytica card samples could be tested consis-
tently positive up to the dilution step of 1 : 16. One conven-
tional sample tested positive one dilution step lower (1 : 8)
(Table 1).
3.2. Serial Dilutions of Norovirus GI/GII Samples. Concern-
ing the norovirus samples, the LPDs for the norovirus GI
and GII samples varied significantly between the different
initial samples ranging from 10−2 to the dilution step of
10−8. The results showed a trend towards more sensitivity
in stool card samples. One norovirus GI and two norovirus
GII card samples could be tested positive one dilution step
higher (10−8, 10−8, and 10−4, Table 1) than the corresponding
conventional sample. On the other hand, in one norovirus G
II sample the LPD was one step lower (10−4, Table 1) in the
conventional sample than in the card sample.
3.3. Stability during Storage. On day 0 the pathogen solutions
for C. jejuni and E. histolytica and the native stool samples
for norovirus GI and GII were tested positive according to
the expected pathogen. Testing of the stool card samples at
the designated time points of days 0, 7, 14, 21, 28, 35, and
42 showed positive results for C. jejuni in 41/42 samples
(detection rate of 97.6%) and all samples ofE. histolytica tested
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positive (detection rate of 100%). Concerning the norovirus
GI samples, 41/42 samples tested positive (detection rate of
97.6%) and all norovirus GII samples tested positive (detec-
tion rate of 100%) (Table 2). One norovirus GI sample tested
consistently positive for Cryptosporidium spp. (Table 2). The
unexpected positive result for Cryptosporidium spp. could be
confirmed in the original stool sample by microscopy and
antigen testing by ProSpecT Cryptosporidium Microplate
Assay (Oxoid, Hants, UK).
4. Discussion
This study evaluatedHemoccult cards as a collection and stor-
age tool of stool samples in combination with a commercially
available multiplex PCR able to detect viral, bacterial, and
protozoal organisms relevant for the etiology of TD. In the
dilution trial the native samples and the samples on stool
cards of C. jejuni and E. histolytica reached mostly consis-
tent LPCs showing no reduced detection of the expected
pathogens when stool cards were used as a sample collection
tool. Comparing the native and stool card norovirus samples
the results suggest that detection from stool cards is also
similar to conventional stool samples. As we could perform
only two replicates at each concentration to limit the costs
for the testing, our results remain preliminary and larger
studies are needed to confirm the LPDs/LPCs and the repro-
ducibility. As the LPDs/LPCs concerning the conventional
and card samples were all below the LoDs of the GPP, a loss
of sensitivity using the Hemoccult cards is unlikely.
Lalani et al. used FTA Elute Cards for sample storage
and found also comparable detectable concentrations for C.
jejuni and norovirus in the conventional and card samples
[16]. After one week of storage on FTA cards the detectable
concentrations for C. jejuni on card samples were 105 CFU/g
and 103 plaque forming units (PFU) for norovirus GI and
norovirus GII. In the present study determination of CFUs
for C. jejuni was not performed and the relationship between
CFUs and bacterial count is therefore unclear.The LPCs were
ranging from 25.000 bacteria/g (dilution step 1 : 4) to 12.500
bacteria/g (dilution step 1 : 8). In our study the provided
norovirus samples showed a wide range of initial norovirus
concentration. The LPDs for the different samples ranged
from dilution step 10−2 to dilution step of 10−8 (Table 1).
These results could be confirmed after repeating the testing
with a commercially available real-time PCR for norovirus
(Microgen). As the results were comparable between native
and Hemoccult card samples, usage of Hemoccult cards is
also feasible at varying norovirus concentrations.
In the storage trial the model pathogens (C. jejuni, E.
histolytica, norovirus) could be detected reliably from the
card samples at weekly intervals for up to six weeks. Grimes
et al. could show the possibility of storage of E. coli stool
samples on cards with successful detection by PCR for up to
14 months [9]. In contrast to this study no developer/fixative
was used on the card samples of the present study. This
increases the feasibility of the method as only a small amount
of stool has to be put on the detection field and no additional
developer/fixative fluid has to be carried along by the traveler.
Additionally, in the context of an epidemiologic study no
costs for this substance for each traveler will accrue. Lalani
et al. could also successfully store stool samples spiked with
several bacterial, protozoal, and viral pathogens including C.
jejuni and norovirus GI/II for up to three months on FTA
Elute Cards although C. jejuni was only detectable for up to
one month [16]. Compared to Hemoccult cards FTA Elute
Cards are more expensive and Hemoccult cards may be more
convenient for travelers as the detection fields are readily
covered by a carton wrapping and lid to prevent spoiling.
Several points warrant attention. Norovirus samples
acquired from the reference laboratory were sent there
for exclusive testing for norovirus from different unknown
sources. Information on further pathogens in these samples
was not available to us. Therefore, the detection of additional
pathogens like the Cryptosporidium spp. in one norovirus GI
sample can be explained. By chance, this showed that another
protozoal pathogen could be stored and detected on stool
cards for up to six weeks. This is in contrast to the results of
Lalani et al. who had difficulties detecting Cryptosporidium
spp. from spiked card samples [16]. Possibly, although we
have only one sample with this pathogen, this could be an
effect of our different extractionmethod usingMiniMag.This
result warrants further investigation.
As the study was done as a proof of concept study, storage
was checked only at room temperature. Storage at higher
temperature simulating travel to tropical countries was not
checked, as the cost of GPP testing is very high and the num-
ber of samples and testing processes was therefore restricted.
On the other hand, Lalani et al. found no effect of varying
environmental conditions when the card samples were stored
at 4∘C or 31∘Cwith the exception ofCryptosporidium spp. and
C. jejuni that could be either poorly or not detected in that
setting [16].
Additionally, in order to limit the cost of testing we could
not repeat our examinations with unmodified infected stool
samples and only a limited number of replicates could be
performed. Unfortunately, the viral loads cannot be reported
for the used norovirus samples and only Ct values can be
shown semiquantitatively as these were samples from routine
clinical testing and therefore not exactly quantified. On the
other hand, the viral loads in our samples should thus reflect
viral loads seen in norovirus patients in general.
Altogether, this study suggests that stool cards are a
reliable tool for collecting stool samples for multiplex PCR-
testing. Storage for up to 6 weeks at room temperature allows
detection of viral, bacterial, and protozoal organisms. There-
fore, this method could for example be used in studies on the
etiology of TD or in the evaluation of prophylactic measures
as the use of antibiotics or vaccines. Further studies on the
feasibility of these cards during travel are therefore needed.
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